KALA BIO, Inc.
Developing stem cell-based biologics for rare and serious eye diseases.
KALA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US4831192020
- LEI:
- Country:
- United States of America
- Address:
- 1167 MASSACHUSETTS AVENUE, 2476 ARLINGTON
- Website:
- https://www.kalarx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
KALA BIO, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare and serious eye diseases. The company leverages its proprietary mesenchymal stem cell secretome (MSC-S) platform to create treatments with regenerative effects for ocular surface and retinal conditions. KALA BIO's development pipeline is led by KPI-012, a topical therapy in a Phase 2b clinical study for persistent corneal epithelial defect (PCED). It is also advancing KPI-014, a preclinical program for rare inherited retinal diseases. Following the 2022 sale of its two FDA-approved commercial products, EYSUVIS® and INVELTYS®, to Alcon Inc., the company has shifted its strategic focus to the research and development of novel biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all KALA BIO, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for KALA BIO, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for KALA BIO, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
